The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic.
Ang (1–7)
MAS1
Prostate cancer
Renin-angiotensin system
SARS-CoV-2
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
20
05
2022
accepted:
03
11
2022
pubmed:
9
12
2022
medline:
3
2
2023
entrez:
8
12
2022
Statut:
ppublish
Résumé
The renin-angiotensin system is known to maintain blood pressure and body fluids. However, it has been found to consist of at least two major constituents, the classic and the alternative pathway, balancing and supporting each other's signalling in a very intricate way. Current research has shown that the renin-angiotensin system is involved in a broad range of biological processes and diseases, such as cancer and infectious diseases. We conducted a literature review on the interaction of the renin-angiotensin system and prostate cancer and explored the research on the possible impact of the SARS-CoV-2 virus in this context. This review provides an update on contemporary knowledge into the alternative renin-angiotensin system, its role in cancer, specifically prostate cancer, and the implications of the current COVID-19 pandemic on cancer and cancer care. In this work, we aim to demonstrate how shifting the RAS signalling pathway from the classic to the alternative axis seems to be a viable option in supporting treatment of specific cancers and at the same time demonstrating beneficial properties in supportive care. It however seems to be the case that the infection with SARS-CoV-2 and subsequent impairment of the renin-angiotensin-system could exhibit serious deleterious long-term effects even in oncology.
Sections du résumé
BACKGROUND
BACKGROUND
The renin-angiotensin system is known to maintain blood pressure and body fluids. However, it has been found to consist of at least two major constituents, the classic and the alternative pathway, balancing and supporting each other's signalling in a very intricate way. Current research has shown that the renin-angiotensin system is involved in a broad range of biological processes and diseases, such as cancer and infectious diseases.
METHODS AND RESULTS
RESULTS
We conducted a literature review on the interaction of the renin-angiotensin system and prostate cancer and explored the research on the possible impact of the SARS-CoV-2 virus in this context. This review provides an update on contemporary knowledge into the alternative renin-angiotensin system, its role in cancer, specifically prostate cancer, and the implications of the current COVID-19 pandemic on cancer and cancer care.
CONCLUSION
CONCLUSIONS
In this work, we aim to demonstrate how shifting the RAS signalling pathway from the classic to the alternative axis seems to be a viable option in supporting treatment of specific cancers and at the same time demonstrating beneficial properties in supportive care. It however seems to be the case that the infection with SARS-CoV-2 and subsequent impairment of the renin-angiotensin-system could exhibit serious deleterious long-term effects even in oncology.
Identifiants
pubmed: 36478297
doi: 10.1007/s11033-022-08087-5
pii: 10.1007/s11033-022-08087-5
pmc: PMC9734445
doi:
Substances chimiques
Renin
EC 3.4.23.15
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensins
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1809-1816Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ballew JR, Fink GD (2001) Characterization of the antihypertensive effect of a thiazide diuretic in angiotensin II-induced hypertension. J Hypertens 19(9):1601–1606
doi: 10.1097/00004872-200109000-00012
Pinter MJ, Rakesh K (2017) Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 9(410):5616
doi: 10.1126/scitranslmed.aan5616
Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271-280e8
doi: 10.1016/j.cell.2020.02.052
Wu Q et al (2017) Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 7(1):9110
doi: 10.1038/s41598-017-09536-z
Saha A, Anirvan P (2020) Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition. Ecancermedicalscience 14:1099
doi: 10.3332/ecancer.2020.1099
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68:394–4246
Mishra JS, Hankins GD, Kumar S (2016) Testosterone downregulates angiotensin II type-2 receptor via androgen receptor-mediated ERK1/2 MAP kinase pathway in rat aorta. J Renin Angiotensin Aldosterone Syst. https://doi.org/10.1177/1470320316674875
doi: 10.1177/1470320316674875
Melloni C, Roe MT (2020) Androgen deprivation therapy and cardiovascular disease. Urol Oncol 38(2):45–52
doi: 10.1016/j.urolonc.2019.02.010
Chakravarty D et al (2020) Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol 3(1):374
doi: 10.1038/s42003-020-1088-9
Montopoli M et al (2020) Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 31(8):1040–1045
doi: 10.1016/j.annonc.2020.04.479
George AJ, Thomas WG, Hannan RD (2010) The renin–angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745–759
doi: 10.1038/nrc2945
Uemura H et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2(11):1139–1147
Haendeler J, Dimmeler S, Unger T, Schölkens BA (2004) Regulation of angiogenesis by angiotensin II, vol I. Springer, Berlin Heidelberg: Berlin, Heidelberg, pp 99–109
Domińska K et al (2012) Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 37(2):200–206
doi: 10.1016/j.peptides.2012.07.022
Chauhan VP et al (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4:2516
doi: 10.1038/ncomms3516
Zhang Q et al (2019) Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res 38(1):116
doi: 10.1186/s13046-019-1127-x
Siltari A et al (2020) Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE 15(6):e0234269
doi: 10.1371/journal.pone.0234269
Smith L et al (2020) Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med 20(3):409–416
doi: 10.1007/s10238-020-00622-7
Domińska K et al (2016) Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells. Int J Oncol 48(6):2619–2628
doi: 10.3892/ijo.2016.3458
Chappell MC (2007) Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50(4):596–599
doi: 10.1161/HYPERTENSIONAHA.106.076216
Bosnyak S et al (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121(7):297–303
doi: 10.1042/CS20110036
Jiang F et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol 11(7):413–426
doi: 10.1038/nrcardio.2014.59
Tetzner A et al (2016) G-protein-coupled receptor MrgD is a receptor for angiotensin-(1–7) involving adenylyl cyclase, cAMP, and phosphokinase. Hypertension, 68(1), 185
Peiró C et al (2007) Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor mas: a new target to improve endothelial function. J Hypertens 25(12):2421–2425
doi: 10.1097/HJH.0b013e3282f0143c
Walther T et al (1998) Sustained long term potentiation and anxiety in mice lacking the mas protooncogene. J Biol Chem 273(19):11867–11873
doi: 10.1074/jbc.273.19.11867
Zhao Y et al (2010) Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 225(1):168–173
doi: 10.1002/jcp.22209
Bernardi S et al (2012) Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 13(1):202–209
doi: 10.1177/1470320311426023
Feng Y et al (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 23(4):941–948
Zhou L et al (2011) Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett 307(1):18–25
doi: 10.1016/j.canlet.2011.03.011
Krishnan B et al (2013) Angiotensin-(1–7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate 73(1):71–82
doi: 10.1002/pros.22542
Zheng S et al (2015) Ang-(1–7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun 460(2):333–340
doi: 10.1016/j.bbrc.2015.03.035
Burns WC et al (2010) Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1–7/MAS-1-dependent pathways. Am J Physiol Renal Physiol 299(3):F585–F593
doi: 10.1152/ajprenal.00538.2009
Ye G et al (2015) The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun 459(1):18–23
doi: 10.1016/j.bbrc.2015.02.030
Yu C et al (2016) Downregulation of ACE2/Ang-(1–7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Lett 376(2):268–277
doi: 10.1016/j.canlet.2016.04.006
Zhou L et al (2009) Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med 217(2):123–131
doi: 10.1620/tjem.217.123
Zong H et al (2015) Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumour Biol 36(7):5171–5177
doi: 10.1007/s13277-015-3171-2
Zhang Q et al (2019) ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Experimental Clin Cancer Res 38(1):173
doi: 10.1186/s13046-019-1156-5
Khanna P et al (2021) ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1–7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med 13(577):170
doi: 10.1126/scitranslmed.abc0170
Luo Y et al (2015) Expression of MAS1 in breast cancer. Cancer Sci 106(9):1240–1248
doi: 10.1111/cas.12719
Lässig F et al (2021) Expression of canonical transient receptor potential channels in U-2 OS and MNNG-HOS osteosarcoma cell lines. Oncol Lett 21(4):307
doi: 10.3892/ol.2021.12568
Gallagher PE et al (2014) Angiotensin-(1–7): a peptide hormone with anti-cancer activity. Curr Med Chem 21(21):2417–2423
doi: 10.2174/0929867321666140205133357
Krishnan B et al (2013) Angiotensin-(1–7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate 73(1):60–70
doi: 10.1002/pros.22540
Murphy KT et al (2019) Mas receptor activation slows tumor growth and attenuates muscle wasting in cancer. Cancer Res 79(4):706–719
doi: 10.1158/0008-5472.CAN-18-1207
Nishimura S et al (2012) MRGD, a MAS-related G-protein coupled receptor, promotes tumorigenisis and is highly expressed in lung cancer. PLoS ONE 7(6):e38618
doi: 10.1371/journal.pone.0038618
Soto-Pantoja DR et al (2009) Angiotensin-(1–7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 8(6):1676–1683
doi: 10.1158/1535-7163.MCT-09-0161
Chen X et al (2017) AAV-Mediated angiotensin 1–7 overexpression inhibits tumor growth of lung cancer in vitro and in vivo. Oncotarget 8(1):354–363
doi: 10.18632/oncotarget.13396
Pei N et al (2016) Angiotensin-(1–7) decreases cell growth and angiogenesis of human nasopharyngeal carcinoma xenografts. Mol Cancer Ther 15(1):37–47
doi: 10.1158/1535-7163.MCT-14-0981
Lin YT et al (2018) Pre-treatment with angiotensin-(1–7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts. J Mol Med (Berl) 96(12):1407–1418
doi: 10.1007/s00109-018-1704-z
Domińska K et al (2018) Influence and mechanism of Angiotensin 1–7 on biological properties of normal prostate epithelial cells. Biochem Biophys Res Commun 502(1):152–159
doi: 10.1016/j.bbrc.2018.05.138
Domińska K et al (2020) The impact of Ang-(1–9) and Ang-(3–7) on the biological properties of prostate cancer cells by modulation of inflammatory and steroidogenesis pathway genes. Int J Mol Sci 21(17):6227
doi: 10.3390/ijms21176227
Caffo O et al (2020) On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. Ann Oncol 31(10):1415–1416
doi: 10.1016/j.annonc.2020.06.005
Rastrelli G et al (2020) Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology 9:88–98
doi: 10.1111/andr.12821
Mjaess G et al (2020) COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol 30(10):484–487
doi: 10.1016/j.purol.2020.05.007
Banu N et al (2020) Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications. Life Sci 256:117905
doi: 10.1016/j.lfs.2020.117905
Li W et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450–454
doi: 10.1038/nature02145
Acconcia F (2020) The network of angiotensin receptors in breast cancer. Cells 9(6):1336
doi: 10.3390/cells9061336
Feldman R et al (2020) Aldosterone mediates a mineralocorticoid receptor-mediated increase in prostate cancer cell migration. FASEB J 34(S1):1–1
Dhondt B et al (2019) Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg 74(6):439–444
doi: 10.1080/17843286.2018.1543827
Ishida J, Fukamizu A (1999) Angiotensin II and apoptosis. Nihon Rinsho 57(5):1117–1123
von Amsberg G, Merseburger AS (2020) Treatment of metastatic, castration-resistant prostate cancer. Urologe A 59(6):673–679